Chugai Sets Record Results In 2009, Lowers Forecasts For 2010
This article was originally published in PharmAsia News
Executive Summary
Roche Japanese unit Chugai Pharmaceutical had its best year ever in 2009, posting record revenue and profits thanks largely to Tamiflu (oseltamivir), which saw Japan sales soar nine-fold to ¥76.2 billion ($852.75 million) in response to the Japanese government and local authorities stockpiling flu drugs
You may also be interested in...
Japan To Lower Price Of Eight Drugs From Takeda, Novartis, BMS And Chugai By 12-18 Percent
As part of an ongoing re-pricing policy for drugs that have seen expanded market share, Japan's Ministry of Health, Labor and Welfare has decided to lower the price on eight drugs effective April 1
Japan To Lower Price Of Eight Drugs From Takeda, Novartis, BMS And Chugai By 12-18 Percent
As part of an ongoing re-pricing policy for drugs that have seen expanded market share, Japan's Ministry of Health, Labor and Welfare has decided to lower the price on eight drugs effective April 1
Daiichi Sankyo Lifts FY2009 Profit Forecasts, Submits NDA For Flu Inhaler Laninamivir
Daiichi Sankyo Jan. 29 lifted profit estimations for fiscal year 2009, citing favorable exchange rates for the Indian rupee against the U.S. dollar, as well as improvements in subsidiary Ranbaxy Laboratories